Simultaneous inhibition of the constitutively activated nuclear factor κB and of the Interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cell Cycle

• Publication date

  2008-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.7.20.6832PMID 18931595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The emerging role of novel therapies for the treatment of relapsed myeloma.

  2007cited by this paper
• Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo

  2005cited by this paper
• Serial Review : The powerhouse takes control of the cell : The role of mitochondria in signal transduction Serial Review

  2004cited by this paper
• Adenovirus vectors: biology, design, and production.

  2004cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells*

  2003cited by this paper
• Regulation of apoptosis by ubiquitination

  2003cited by this paper
• Not just research tools—proteasome inhibitors offer therapeutic promise

  2002cited by this paper
• Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

  2002cited by this paper
• The proteasome: a new target for novel drug therapies.

  2001cited by this paper
• Mitochondrial targeting of JNK/SAPK in the phorbol ester response of myeloid leukemia cells

  2001cited by this paper
• Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

  2001cited by this paper
• Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma

  2001cited by this paper
• Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis.

  2001cited by this paper
• Optimization of the helper-dependent adenovirus system for production and potency in vivo.

  2000cited by this paper
• Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-xL in Response to DNA Damage*

  2000cited by this paper
• Prolonged Expression and Effective Readministration of Erythropoietin Delivered with a Fully Deleted Adenoviral Vector

  2000cited by this paper
• Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

  2000cited by this paper
• Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.

  1999cited by this paper
• Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin

  1999cited by this paper
• NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis

  1999cited by this paper
• Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection

  1999cited by this paper
• Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.

  1999cited by this paper
• The Rel/NF-kappaB signal transduction pathway: introduction.

  1999cited by this paper
• Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells.

  1998cited by this paper
• The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death.

  1998cited by this paper
• Ikappa Balpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappaB.

  1998cited by this paper
• The retinoblastoma susceptibility gene RB-1 in multiple myeloma.

  1997cited by this paper
• Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.

  1997cited by this paper
• IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

  1997cited by this paper
• Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.

  1996cited by this paper
• Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.

  1996cited by this paper
• Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B

  1995cited by this paper
• Deletion of the retinoblastoma gene in multiple myeloma.

  1994cited by this paper
• Mutations of the p53 gene in human myeloma cell lines.

  1992cited by this paper
• Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.

  1989cited by this paper
• Nuclear factor– (cid:1) B and STAT3 are constitutively active in CD138 (cid:2) cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

  year unknowncited by this paper

• Molecular targets and mechanisms of anti-cancer effects of withanolides.

  2023cites this paper
• Emerging hallmarks of endometriosis metabolism: A promising target for the treatment of endometriosis.

  2022cites this paper
• Withaferin A: From Ancient Remedy to Potential Drug Candidate

  2021cites this paper
• Daturataturin A, a withanolide in Datura metel L., induces HaCaT autophagy through the PI3K‐Akt‐mTOR signaling pathway

  2021cites this paper
• Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.

  2018cites this paper
• Withania somnifera: From Traditional Use to Evidence Based Medicinal Prominence

  2017cites this paper
• Withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells.

  2017cites this paper
• Effect of levamisole on expression of CD138 and interleukin-6 in human multiple myeloma cell lines.

  2017cites this paper
• Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment

  2016cites this paper
• Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments

  2016cites this paper
• Drugs acting on homeostasis: challenging cancer cell adaptation

  2015influential citation
• Soluble CD54 induces human endothelial cells ex vivo expansion useful for cardiovascular regeneration and tissue engineering application

  2015cites this paper
• Doxycycline speeds up healing of chronic venous ulcers

  2015cites this paper
• Potential Anticancer Properties and Mechanisms of Action of Withanolides.

  2015cites this paper
• Withaferin A Inhibits STAT3 and Induces Tumor Cell Death in Neuroblastoma and Multiple Myeloma

  2014cites this paper
• Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.

  2014cites this paper
• In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients.

  2014cites this paper
• Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis

  2014cites this paper
• Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

  2014cites this paper
• Plant coumestans: recent advances and future perspectives in cancer therapy.

  2014cites this paper
• Resistance of Multiple Myeloma to Proteasome Inhibitors

  2014cites this paper
• Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

  2014cites this paper
• Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract

  2013cites this paper
• Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.

  2013cites this paper
• Chronic venous leg ulcers are associated with high levels of metalloproteinases‐9 and neutrophil gelatinase‐associated lipocalin

  2013cites this paper
• Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF‐κB in lung cancer and in normal pulmonary tissues

  2013cites this paper
• Regulation of molecular processes in diffuse large b-cell lymphoma

  2013cites this paper
• The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial.

  2013cites this paper
• The Nuclear Factor Kappa-B Signaling Pathway as a Therapeutic Target Against Thyroid Cancers

  2012cites this paper
• Targeted Inhibition of Multiple Proinflammatory Signalling Pathways for the Prevention and Treatment of Multiple Myeloma

  2012cites this paper
• Molecular insight in the multifunctional activities of Withaferin A.

  2012cites this paper
• Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo

  2012cites this paper
• Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.

  2012cites this paper
• Age Dependent Switching Role of Cyclin D1 in Breast Cancer

  2012cites this paper
• Inhibition of topoisomerase IIα: novel function of wedelolactone.

  2011cites this paper
• Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells.

  2011cites this paper
• Inhibition of topoisomerase IIa: Novel function ofwedelolactone

  2011cites this paper
• Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.

  2010cites this paper
• The Anticancer Effects of Vitamin E Derivative alpha-TEA in Human Hematological Malignancies APPROVED BY SUPERVISING COMMITTEE:

  2010cites this paper
• The Fanconi anemia (FA)/BRCA DNA damage repair pathway is regulated by NF-kappaB and mediates drug resistance in multiple myeloma

  2010cites this paper
• Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies

  2010cites this paper
• Serum markers of apoptosis decrease with age and cancer stage

  2009cites this paper
• Targeting transcription factor NFκB: comparative analysis of proteasome and IKK inhibitors

  2009cites this paper
• Natural and synthetic α,β-unsaturated carbonyls for NF-κB inhibition.

  2009cites this paper
• Generation of Monoclonal Antibodies to Surface Proteins of Human Multiple Myeloma Employing Membrane Extracts for Murine In Vivo Immunizations

  2009influential citation
• Immunology at The University of Iowa

  2007cites this paper